These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 36030212)
21. Construction of Pyroptosis-Related Prognostic and Immune Infiltration Signature in Bladder Cancer. Du X; Zhao X; Tang Y; Tang W Dis Markers; 2022; 2022():6429993. PubMed ID: 36569221 [TBL] [Abstract][Full Text] [Related]
22. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer. Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P Front Oncol; 2023; 13():972558. PubMed ID: 37064115 [TBL] [Abstract][Full Text] [Related]
23. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer. Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230 [TBL] [Abstract][Full Text] [Related]
24. Construction and validation of a bladder cancer risk model based on autophagy-related genes. Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018 [TBL] [Abstract][Full Text] [Related]
25. Identification of Immune-Related Subtypes and Construction of a Novel Prognostic Model for Bladder Urothelial Cancer. Zhang J; Huang C; Yang R; Wang X; Fang B; Mi J; Yuan H; Mo Z; Sun Y Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421685 [TBL] [Abstract][Full Text] [Related]
26. Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature. Tang C; Fan Y; Zhu S BMC Urol; 2024 Mar; 24(1):69. PubMed ID: 38532369 [TBL] [Abstract][Full Text] [Related]
27. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H Front Immunol; 2023; 14():1122570. PubMed ID: 37275895 [TBL] [Abstract][Full Text] [Related]
28. PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma. Li P; Qiao G; Lu J; Ji W; Gao C; Qi F Math Biosci Eng; 2022 Jan; 19(1):169-190. PubMed ID: 34902986 [TBL] [Abstract][Full Text] [Related]
29. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer. Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M Cancer Manag Res; 2022; 14():67-88. PubMed ID: 35023971 [TBL] [Abstract][Full Text] [Related]
30. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs. Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H Front Immunol; 2022; 13():916800. PubMed ID: 35860239 [TBL] [Abstract][Full Text] [Related]
31. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence. Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881 [TBL] [Abstract][Full Text] [Related]
32. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma. Mi Y; Wang X J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952 [TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma. Zhu S; Li H; Fan Y; Tang C BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989 [TBL] [Abstract][Full Text] [Related]
34. A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma. Zhou Z; Zhou Y; Liu W; Dai J Front Genet; 2023; 14():1148430. PubMed ID: 37065485 [TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787 [TBL] [Abstract][Full Text] [Related]
36. Identification and validation of prognostic signature genes of bladder cancer by integrating methylation and transcriptomic analysis. Chatterjee D; Mou SI; Sultana T; Hosen MI; Faruk MO Sci Rep; 2024 Jan; 14(1):368. PubMed ID: 38172584 [TBL] [Abstract][Full Text] [Related]
37. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB. Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S Front Immunol; 2023; 14():1253586. PubMed ID: 37790935 [TBL] [Abstract][Full Text] [Related]
38. A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder cancer. Wu L; Chen W; Cao Y; Chen B; He Y; Wang X Aging (Albany NY); 2023 Jul; 15(13):6445-6466. PubMed ID: 37424068 [TBL] [Abstract][Full Text] [Related]
39. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes. Qiu H; Hu X; He C; Yu B; Li Y; Li J Front Genet; 2020; 11():12. PubMed ID: 32117435 [TBL] [Abstract][Full Text] [Related]
40. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation. Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P Front Immunol; 2023; 14():955949. PubMed ID: 37006317 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]